Biomarkers in Brain Disease
Monday, January 26, 2009 - Wednesday, January 28, 2009
Presented By
Presented by The New York Academy of Sciences and The Global Medical Excellence Cluster of South East England
Advances in biomarker development are revolutionizing the way we study, diagnose, and treat disease. However, progress in the development and use of biomarkers for diseases of the central nervous system has been limited by a number of difficulties - including inherent barriers associated with studying the brain.
Development of reliable biomarkers for brain disorders would dramatically accelerate research on the etiology, pathophysiology, disease progression, and therapeutic development of many very prevalent and devastating diseases including Alzheimer's, Parkinson's, multiple sclerosis, and others.
During this two-day meeting, international experts will gather to discuss the latest advances in biomarker technologies and biomarker development for brain disorders, as well as the logistical, regulatory, and funding challenges experienced by scientists working on clinical trials for biomarkers.
Scientific Organizing Committee:
- Sabine Bahn, Cambridge University, UK
- Karima Boubekeur, Roche, Switzerland
- Maria Carrillo, Alzheimer's Association, USA
- David Hawkes, University College, London
- Andrew Lockhart, GlaxoSmithKline, UK
- Simon Lovestone, Kings College, London
- Richard Mayeux, Columbia, New York
- Jeremy Nicholson, Imperial College, London
- Ian Pike, Proteome Sciences, UK
- Bill Potter, Merck, USA
- Barbara Sahakian, University of Cambridge, UK
- Gordon Wilcock, University of Oxford, UK
- Kathy Granger, The New York Academy of Sciences, USA
Sponsors
Silver sponsors
Merck Serono S.A. Geneva
Bronze sponsors
- Imperial College
- Johnson & Johnson
- King's College, London
- Oxford University
- The Ellison Medical Foundation
- University College, London
- Wellcome Trust
Academy Friends
- Alzheimer's Association
- BIOBASE GmbH
- Eisai
- Foresight Programme, Government Office for Science
- Rules-Based Medicine, Inc
- Schering-Plough Research Institute
- Scout Diagnostics
- The Alzheimer's Research Trust